The pharmaceutical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for managing obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a significant substantial loss in body mass and enhance metabolic function